Clinical Trial Update: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating tagraxofusp in combination with low-intensity chemotherapy for CD123-positive relapsed or refractory acute lymphoblastic leukemia and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• Tagraxofusp (tagraxofusp)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-08-11